Second quarter summary
NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner
Focus on genetic mitochondrial diseases
NeuroVive out-licenses targeted LHON therapy to BridgeBio
Strategic in-licensing broadens the project portfolio
Negative top-line result of phase III study and continued progress in other clinical projects
NeuroVive's research wins award at international research symposium
Milestones achieved consolidate positioning in mitochondrial medicine Six months (1 Jan. 2013 - 30 Jun. 2013) · Net revenues were SEK 5,335,000 (0) and other operating income was SEK 863,000 (31 ...